trending Market Intelligence /marketintelligence/en/news-insights/trending/tlryod9kpmqf_18g4hg78a2 content esgSubNav
In This List

Astellas, Seattle Genetics cancer drug gets FDA breakthrough therapy status

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Astellas, Seattle Genetics cancer drug gets FDA breakthrough therapy status

The U.S. Food and Drug Administration granted breakthrough therapy designation to Astellas Pharma Inc. and Seattle Genetics Inc.'s urothelial cancer drug enfortumab vedotin.

Urothelial cancer, or transitional cell cancer, is the most common type of cancer affecting the bladder.

The drug is intended to treat patients with urothelial cancer that progressed locally or has spread to other parts of the body and have been previously treated with checkpoint inhibitors. Checkpoint inhibitors work by blocking certain proteins produced by some types of immune system cells and cancer cells.

The designation was based on the early results of a phase 1 study evaluating enfortumab vedotin as a monotherapy.

Japanese Astellas and Seattle Genetics are evaluating enfortumab vedotin in another trial, EV-103, in combination with checkpoint inhibitor therapy. The two companies are also investigating the drug to treat solid tumors, such as ovarian and non-small cell lung carcinoma.